Financings in Brief: Gliatech
This article was originally published in The Gray Sheet
Executive SummaryGliatech: Files registration statement with the Securities and Exchange Commission for an initial public offering of 2.3 mil. shares of its common stock. Shares are expected to be sold for between $10 and $12 each, the company says. Gliatech manufactures the Adcon line of products to control surgical adhesion. The Cleveland, Ohio-based company currently is conducting U.S. clinical trials of its Adcon-L and Adcon-T/N gels, for prevention of adhesions in lumbar and tendon/peripheral nerve surgeries, respectively. Montgomery Securities, Vector Securities International, and McDonald & Company Securities will co-manage the offering, Gliatech says...
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.